Brian Mills, PhD, joined Pivotal Life Science’s investment team in 2022. Prior to Pivotal, he was a research analyst at Jefferies covering the biotechnology sector. Prior to Jefferies, Brian was a postdoctoral scholar at Stanford University where he worked to develop translational biomarkers for a range of neurological and psychiatric diseases. He earned his PhD in neuroscience from Oregon Health and Science University (OHSU) and has published over 20 peer reviewed articles in top journals.
